anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lyme disease is the most common vector borne disease in the United States. Although antibiotic therapy is clinically effective in treating the symptoms of Lyme disease for most patients early in the course of disease, a significant number of patients who receive therapy report persistent symptoms. The cause of persistent symptoms after antibiotic therapy for Lyme disease is an area of great controversy. Recent studies have shown that the organism (Borrelia burgdorferi) may persist in animals after antibiotic therapy and can be detected by using the natural tick vector (Ixodes scapularis) to acquire the organism through feeding (xenodiagnosis). Whether this occurs in humans is unknown. Currently available tests for human Lyme disease do not allow determination of persistent infection after antibiotic therapy.

In this proposal, the utility of xenodiagnosis for identifying persistence of B. burgdorferi in treated human Lyme disease will be tested in up to 120 subjects with various stages of Lyme disease with 30 healthy adults to serve as controls. Subjects will be followed for approximately 3 months. In Objective #1, subjects who have the characteristic erythema migrans (EM) rash and have been treated with antibiotics early (within 3 weeks of infection) in the course of Lyme disease will be tested. After completion of antibiotic therapy, 25-30 larval Ixodes ticks will be allowed to feed on the subject and biopsies of the EM site will be performed. Repleted ticks will be collected and tested for the presence of B. burgdorferi. In Objective #2, similar studies will be performed, but enrollment will target subjects with elevated C6 (region 6 of the VlsE surface protein of B. burgdorferi) antibody levels. In Objective #3, patients with persistent symptoms after antibiotic therapy will be evaluated. As an attempt to increase the chances of a positive xenodiagnosis in humans, patients with EM who are in the first 2 days of antibiotic therapy and patients with untreated Lyme arthritis will also be evaluated. Evidence that B. burgdorferi can be recovered by xenodiagnosis after antibiotic therapy in subjects with continued symptoms would change the current paradigm for potential mechanisms of disease and provide researchers and clinicians a tool for identifying patients with persistent infection. In Objective #4 we will assess the safety of the planned xenodiagnostic procedure in humans. All individuals who underwent xenodiagnosis under the study will be assessed for adverse events.
This cohort must have Melanoma that has progressed after/or on treatment with an immune checkpoint inhibitor (CPI) and have received 1-2 prior lines of therapy for their advanced/metastatic disease. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
1471204 Reciprocating pumps BIORESPONSE Inc 2 April 1974 [9 April 1973] 14576/74 Heading F1A [Also in Divisions A5 B2 and C6] A pair of piston pumps 201, Fig. 14, also Fig. 15 (not shown), chain driven by a motor 200 has driving screws 203, 204 of the respective pumps threaded in opposite directions and limit switches 222, 223, controlling the direction of rotation of the motor and thereby the extent of travel of the pistons 214 and plastic membranes 220. The pumps may be used to move calibrated amounts of aqueous saline containing preservative, anti-rust agent and fluorescein as a marker in a circuit controlling the volumes of a series of thinwalled, silicone rubber bags for the circulation of biological fluid to and from an animal. Fig. 13, depicts a bag 12 disposed in a housing 14 of rigid polycarbonate fitted with inlet conduits 15, 16 and outlet conduits 17, 18 for the pumped aqueous saline. Parts 19, 20 are solenoid valve blades. In a preferred embodiment two sets of pumps (712, 715 and 729, 730), Fig. 10 (not shown), are used for effecting the withdrawal of lymph fluid from an animal and returning to it lymph fluid free of lymphocytes together with replacement lymph fluid from other animals and physiological saline.
A method for communicating information relating to test results of a user includes obtaining test results of a user. An assertion is derived from the test results of the user. The test results are input to a pre-provisioned first algorithm. The assertion is encapsulated in a first data object by a PGE that controls an environment in which the first algorithm is executed. A first proof is generated which is configured to be usable to verify that the first algorithm used the test results to produce the assertion when provided to a PVE along with the first data object. The test results itself are excluded from the first proof and the first data object such that privacy of the test results is maintained. The first proof and the first data object are communicated to a receiving communication device from an enterprise communication device associated with the user and an enterprise.
FIELD: medicine. SUBSTANCE: method involves administering Annexin labeled with biocompatible radionuclide to the biological object and the object is placed in detection field of radiation detector for building radioactive emission picture a period of time later required for labeled Annexin to reach localization in object organism. The picture is cell death representation in the mentioned object area. The radionuclide is selected from a group composed of iodine 123, iodine 131, Gallium 67, Indium 111, fluorine 18 and Technetium 99m. EFFECT: high visualization accuracy. 28 cl, 4 dwg, 4 tbl
Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
The invention provides a method for 3D planning of the restoration of a tooth. A 3D model of the tooth to be restored is generated on which a root canal treatment is planned or simulated creating a post-treatment 3D model of the tooth. Then, the dimensions of a core build-up to replace missing tooth material in the post-treatment 3D model are determined. A crown restoration is created on the post-treatment 3D tooth. The method then creates a visualization on the post-treatment 3D model of the tooth of a quantitative feedback of the available thickness of the remaining material of the tooth for the restorative crown in order to estimate the risk of fracture of the crown or possible crown perforations. Finally, the method allows selecting or determining an optimal core build-up and sequence of treatment steps for the crown restoration for ensuring tooth strength and successful crown restoration.
BACKGROUND: Many patients with enterostomy and their family caregivers experience severe anxiety and fatigue, which affects their participation in normal social activities and family life, resulting in impaired social function. The purpose of this study was to understand the status of social function of patients with enterostomy and their family caregivers;at the same time to analyze the subjective and objective effects of anxiety and fatigue on their social functions.
METHODS: The self-made general information questionnaire, WHO Social Disability rating Scale, Miao Yu's Multidimensional Fatigue Scale-20 and Zung et al. 's Self-rating Anxiety Scale were used to investigate the general situation, social function, fatigue and anxiety of enterostomy patients and their family caregivers who came to the hospital for treatment from March 28, 2023 to November 30, 2023. SPSS27.0 was used to complete the statistical analysis of the data, and AMOS26.0 was used to establish the structural equation model to complete the subject and object effect analysis.
RESULTS: A total of 260 pairs of enterostomy patients and their family caregivers were included in this study. The social function scores of enterostomy patients and their family caregivers were (8.80±3.44) and (6.44±3.60). The anxiety scores were (37.81±7.60) and (34.73±7.50). The fatigue scores were (63.35±12.80) and (51.21±12.38).The results of the subject-object effect analysis reported the subject effect: the anxiety of patients with enterostomy had a significant positive impact on the degree of social dysfunction (β = 0.154, P = 0.015); The fatigue of patients with enterostomy had a significant positive effect on the degree of social dysfunction (β = 0.132, P = 0.034). The anxiety of family caregivers had a significant positive effect on the degree of social dysfunction (β = 0.161, P = 0.023). The fatigue of family caregivers had a significant positive effect on the degree of social dysfunction (β = 0.201, P = 0.005). In terms of object effects: only the fatigue of family caregivers had a significant positive impact on the degree of social dysfunction of enterostomy patients (β = 0.224, P < 0.001), and other ways had no object effects.
CONCLUSION: Patients with enterostomy and their family caregivers have serious social function defects. Clinical medical staff should take care of them as a whole in order to better return to family and society after surgery.
Tumefactive multiple sclerosis (TMS) is characterized by large demyelinating brain lesions. This was a retrospective cohort study of 67 patients with TMS between January 2015-2023, examining different disease modifying therapy impact on expanded disability scale score change at follow-up. Median age was 36 with a female predominance. Mean EDSS was 3.3 ± 2.3 at TMS onset, 2.1 ± 1.9 at year one, and 2.1 ± 1.9 at last follow-up. A multilinear regression model found higher presentation EDSS and post-diagnosis non-B-cell high efficacy therapies were each independently associated with higher EDSS at last follow up. Further research is needed to determine the value of B-cell therapy in TMS.
The distal radial fracture is one of the most common fractures, with an annual incidence in southern Sweden of 26 per 10,000 inhabitants (Brogren et al. 2007). Non-surgical treatment, predominantly plaster cast or simple splints, comprises the basic treatment in non-displaced fractures, as well as in displaced, but reducible fractures (Handoll and Madhok 2003). In the unstable, non-reducible distal radial fractures, surgical treatment is necessary but can be complex. The choice of method is still controversial (Chen and Jupiter 2007), especially regarding the result over time (Downing and Karantana 2008). External fixation has been the preferred method of operation for decades, but with the introduction of the volar locking plate technique, internal fixation has rapidly become more and more popular, without any solid foundation in the evidence-based medicine (Margaliot et al. 2005).

We have shown in a randomized study that open reduction and internal fixation of distal radial fractures using the TriMed fragment-specific system resulted in better grip strength and forearm rotation at 1-year follow up than closed reduction and bridging external fixation (Abramo et al. 2009). Later we followed up the same cohort at a mean of 5-years, with the primary aim of determining whether the superior results of internal fixation in unstable distal radial fractures persist over time. The conclusion of this study was that, internal fixation is better than external fixation regarding grip strength and forearm rotation at 1-year but the difference disappears at the 5-year follow-up as both groups approach normal values (Landgren et al. submitted in 2010).

The aim of the present study is to compare the subjective, clinical and radiographic outcome of the TriMed fragment-specific system with a volar locking plate in patients with unstable, non-reducible and also redislocated distal radial fractures. The patients who meet all eligibility criteria and provide consent to participate will be randomly assigned to reduction and fixation with either volar locking plate or Trimed fragment-specific system. Patients will undergo physiotherapy, clinical evaluation, radiographic evaluation at fixed intervals and will also include QuickDASH, VAS, SF-12 and EQ5D. There will be 25 patients in each arm and the patients will be followed for 12 months.
Patient Discharges POD #1 and completes survey prior to discharge. Patient given surveys to complete POD #7 at home.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine and to psychiatry. Electroencephalography and coherent analysis of EEG are applied before administration of an oral test dose of Paxyl 20 mg. It is followed with homolateral calculation of the average zonal indexes in the right and left cerebral hemispheres between frontal and anterior temporal, anterior temporal and middle, and between middle and frontal cortical regions. An interhemispheric asymmetry parametre is calculated by dividing the average zonal index in the right hemisphere by the average zonal index of the left hemisphere. If the interhemispheric asymmetry parametre is decreased more than 3.8% as compared with the reference value, a positive effect of Paxyl in the integrated treatment of anxious disorders is predicted. ^ EFFECT: method extends the range of products for prediction of Paxyl effectiveness in the integrated treatment of anxious disorders. ^ 2 ex
A droplet for delivering toothpaste to a user can be provided. The droplet can include a dissolvable outer membrane defining a volume with toothpaste inside the volume. The outer membrane can be formed from dissolvable film strip technology and include a tail or corner portion, which is configured to be embedded into the bristles of a toothbrush. In one aspect of this embodiment, the outer membrane of the droplet can form a pillow-like shape. The droplet further can include one or more extensions coupled to the outer surface of the outer membrane, where the one or more extensions can have a triangular shape, a barb shape or the like. In one aspect of this embodiment, the droplet further can include a logo, a cartoon character, a word or the like printed on the outer membrane. The plurality of extensions can form irregularities on the outer surface of the body section of the outer membrane.
PROBLEM TO BE SOLVED: To obtain a parenterally administrable pharmaceutical preparation having a liposomal state for an active oleophilic compound having a low soplubility, including a short-chain fatty acid at a specific ratio as a stabilizing agent. SOLUTION: Nimodipine or dihydropyridines are used as active compounds and formed in the form of liposomal state having a phospholipid film. The weight ratio of (active compound):(phospholipid) is 1:20-200, the average diameter of the liposome is 35-200 nm, the short-chain fatty acid used as the stabilizing agent is expressed by the formula H3 C-(CH2 )n -COOA ((n) is 4-8; A is a univablent or bivalent cation) and the concentration of the short-chain fatty acid in a ready-to-administer solution is 0.3-10 mg/mL. A disaccharide such as sucrose is preferably added as a cryoprotector in an amount of 0.8-4 pts.wt. based on 1 pt.wt. of the phospholipid. The preparation can be produced by conventional methods, preferably by a high-pressure homogenization such as microfluidization method.
This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 20% less compared to the first repetition.
As with all peptides, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to bivalirudin in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In in vitro studies, bivalirudin exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.  


Among 494 subjects who received bivalirudin in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests. Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed. Nine additional patients who had initial positive tests were negative on repeat testing.
BACKGROUND: To date, there is an ongoing debate regarding the ability to predict PVT development using markers of FVIII or FVIII/PC ratio. This study presents evidence-based medical findings on the influence of FVIII activity levels and FVIII/PC values in the formation of PVT in cirrhosis.
METHODS: The search for original studies on risk factors for portal vein thrombosis (PVT) associated with cirrhosis was conducted, which primarily focused on comparing circulating FVIII activity levels or FVIII/PC ratio in cirrhotic patients with and without PVT. The quality of evidence from each study was assessed using the Newcastle-Ottawa Scale.
RESULTS: The meta-analysis included a total of 10 original studies. In total, 2250 cirrhotic patients were included, with 414 having PVT and 1836 without PVT. The pooled analysis using a random-effects model showed no significant difference in standardized mean difference (SMD) for FVIII activity levels in cirrhotic patients with or without PVT (SMD = 0.12, 95% CI=-0.46 to 0.70, P = 0.68), but there was significant heterogeneity (I2 = 95.52%, P = 0.00). Meta-regression analysis indicated that differences in mean FVIII activity levels in the PVT group, the number of cases in the non-PVT group, and the study design methods partially contributed to the heterogeneity (P < 0.05). However, compared to the non-PVT group, the PVT group had higher FVIII/PC ratio with a statistically significant difference (SMD = 0.39, 95% CI: 0.15 to 0.63, P = 0.00), and there was no significant heterogeneity (I2 = 28.62%).
CONCLUSION: In conclusion, the FVIII/PC ratio not only reflects the severity of liver disease, but also can be used as one of the predictors of PVT development.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition that includes an inositol phosphate dispersed within petroleum jelly through aid of a lipid system and has improved functional activities as skin healing, moisturizing and the like. SOLUTION: A lipid system is added to the system comprising 50-98 wt.% of petroleum jelly and 0.001-40 wt.% of inositol phosphate in an amount of 0.1-30 wt.%. The lipid system preferably contains 0.1-10 wt.% of a phosphatide. The lipid system may additionally contain 0.1-20 wt.% of a 10-22C fatty acid or in addition, 0.1-20 wt.% of sterol. Lecithin is suitable as a phosphatide. In a preferred embodiment, the weight ratio of the petroleum jelly to the inositol phosphate is preferably 5,000/1-5/1. This composition is excellent in the functions as skin conditioning or prevention of skin darkening. This composition may contain water in an amount of 0.8-10 wt.%.
BACKGROUND: In addition to its critical role in neurogenesis, brain-derived neurotrophic factor (BDNF) modulates pain and depressive behaviors.
METHODS: In a translational perspective, we tested the anti-migraine activity of highly purified and characterized recombinant human BDNF (rhBDNF) in an animal model of cephalic pain based on the chronic and intermittent NTG administration (five total injections over nine days), used to mimic recurrence of attacks over a given period. To achieve this, we assessed the effects of two doses of rhBDNF (40 and 80 µg/kg) administered intranasally to adult male Sprague-Dawley rats, on trigeminal hyperalgesia (by orofacial formalin test), gene expression (by rt-PCR) of neuropeptides and inflammatory cytokines in specific areas of the brain related to migraine pain. Serum levels of CGRP, PACAP, and VIP (by ELISA) were also evaluated. The effects of rhBDNF were compared with those of sumatriptan (5 mg/kg i.p), administered 1 h before the last NTG administration.
RESULTS: Both doses of rhBDNF significantly reduced NTG-induced nocifensive behavior in Phase II of the orofacial formalin test. The anti-hyperalgesic effect of intranasal high-dose rhBDNF administration in the NTG-treated animals was associated with a significant modulation of mRNA levels of neuropeptides (CGRP, PACAP, VIP) and cytokines (IL-1beta, IL-10) in the trigeminal ganglion, medulla-pons, and hypothalamic area. Of note, the effects of rhBNDF treatment were comparable to those induced by the administration of sumatriptan. rhBDNF administration at both doses significantly reduced serum levels of PACAP, while the higher dose also significantly reduced serum levels of VIP.
CONCLUSIONS: The findings suggest that intranasal rhBDNF has the potential to be a safe, non-invasive and effective therapeutic approach for the treatment of primary headache, particularly migraine.
Substudy I. The phase angle (PA) determined by electrical bioimpedance is an index of FS with prognostic value in outpatients with cirrhosis, but its usefulness in hospitalized patients has not been studied. Objective: To analyze the prognostic value of PA in hospitalized patients with cirrhosis. Patients and Methods: 100 hospitalized patients with cirrhosis will be consecutively included and PA will be determined by bioimpedance at admission. The correlation between PA and liver function and frailty markers, and the evolution during hospitalization, as well as the incidence of falls, hospitalizations and mortality during follow-up will be analyzed. Substudy II. Given the multidimensional nature of the FS, we propose a multifactorial non-pharmacological intervention based on evidence from previous studies that could be implemented in daily clinical practice. Objective: To evaluate if a multifactorial intervention can improve the FS and decrease the related events (hospitalizations, falls and mortality) in patients with cirrhosis. Patients and Methods: 150 outpatients with cirrhosis will be included and evaluated using the Liver Frailty Index. Frail and pre-frail patients will be randomized into two groups: one group that will receive a multifactorial intervention, consisting of exercise at home, branched-chain amino acids and multispecies probiotic for one year, and one control group. The evolution of the Liver Frailty Index and other parameters (muscle and cognitive function, bioimpedance, risk of falls, quality of life) and biomarkers (miostatin, immune response, microbiota) of FS, and the incidence of hospitalizations, falls and mortality in both groups will be prospectively analyzed.